Symbol="ARDS"
AssetType="Common Stock"
Name="Aridis Pharmaceuticals Inc"
Description="Aridis Pharmaceuticals, Inc., an advanced-stage biopharmaceutical company, is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The company is headquartered in Los Gatos, California."
CIK="1614067"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="5941 OPTICAL COURT, SAN JOSE, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="7959800"
EBITDA="-28162000"
PERatio="None"
PEGRatio="None"
BookValue="-0.773"
DividendPerShare="0"
DividendYield="0"
EPS="-1.37"
RevenuePerShareTTM="0.136"
ProfitMargin="0"
OperatingMarginTTM="-9.58"
ReturnOnAssetsTTM="-1.075"
ReturnOnEquityTTM="0"
RevenueTTM="2986000"
GrossProfitTTM="-22605000"
DilutedEPSTTM="-1.37"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.088"
AnalystTargetPrice="10"
TrailingPE="-"
ForwardPE="2.061"
PriceToSalesRatioTTM="7.33"
PriceToBookRatio="5.4"
EVToRevenue="17.57"
EVToEBITDA="-1.248"
Beta="0.783"
num_52WeekHigh="2.77"
num_52WeekLow="0.15"
num_50DayMovingAverage="0.25"
num_200DayMovingAverage="0.597"
SharesOutstanding="36214000"
DividendDate="None"
ExDividendDate="None"
symbol="ARDS"
open="0.23"
high="0.25"
low="0.21"
price="0.22"
volume="501493.00"
latest_trading_day="2023-07-27"
previous_close="0.24"
change="-0.02"
change_percent="-8.4167%"
aroon_positive_momentum_days="34"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="34"
Volume_recent_avg="3497748"
Change_recent_avg="0.01"
Delta_recent_avg="0.04"
Variance_recent_avg="0.02"
Change_ratio_recent_avg="-1.48"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="34"
Aroon_momentum_negative="66"
image_negative_thumbnail_id_1="1125"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0158.jpeg"
image_negative_thumbnail_id_2="510"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0095.jpeg"
image_neutral_thumbnail_id_1="540"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0059.jpeg"
image_neutral_thumbnail_id_2="582"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0017.jpeg"
image_positive_thumbnail_id_1="948"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0110.jpeg"
image_positive_thumbnail_id_2="703"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0005.jpeg"
image_professor_thumbnail_id_1="1188"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0022.jpeg"
image_professor_thumbnail_id_2="1187"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0021.jpeg"
